Tagomics launches cfDNA platform for multi-organ drug safety monitoring

Cambridge-based precision medicine company Tagomics has launched LiquiPath, a cell-free DNA (cfDNA)-based platform designed to provide non-invasive, multi-organ monitoring of drug safety across preclinical and clinical development.

The company says the platform, described as a first-in-class “liquid pathology” solution, could help drug developers identify treatment-related organ damage earlier and gain greater insight into where toxicity is occurring.

Tagomics has also opened an early access programme for LiquiPath, inviting pharmaceutical and biotechnology companies to collaborate on priority applications, validation studies and future platform development.

A new approach to drug safety monitoring

Therapy-induced toxicity remains a significant challenge in drug development, contributing to clinical trial failures, programme delays, treatment interruptions and potentially irreversible organ damage.

Current approaches to safety monitoring typically combine non-specific biomarkers, imaging and clinical symptoms. According to Tagomics, these methods can detect injury only after significant damage has already occurred.

LiquiPath is designed to address this gap by analysing tissue-specific signals within circulating cfDNA. The platform combines Tagomics’ epigenetic technology, Activace, with proprietary cell-type-specific methylation atlases and deconvolution algorithms to trace cfDNA back to its tissue of origin.

The approach could enable multiple tissues to be assessed from a single blood sample, providing a non-invasive means of monitoring treatment-related adverse effects.

Potential applications across drug development

Tagomics says LiquiPath has been developed for use across preclinical studies, clinical development and post-market surveillance.

In preclinical research, its cross-species and organ-agnostic capabilities could support toxicity-risk stratification while potentially reducing reliance on histopathology and animal studies.

In clinical development, the platform is intended to identify subclinical toxicity earlier, support prediction of adverse events and provide additional information for patient stratification.

The company is already developing LiquiPath through projects with pharmaceutical partners including AstraZeneca, spanning multiple therapeutic modalities and stages of development.

Dr Jack Kennefick, CEO and co-founder of Tagomics, said the launch represents a shift towards more precise approaches to monitoring treatment safety.

He added that the platform could help drug developers “detect toxicity earlier and understand where injury is occurring”, supporting faster decision-making and potentially enabling patients to benefit from new therapies for longer.

Expanding beyond cancer detection

The LiquiPath launch also marks an expansion of Tagomics’ commercial offering beyond its work in cancer detection.

The company, which was founded in 2021 as a spin-out from the University of Birmingham, has developed a multiomic platform combining epigenomics, genomics and fragmentomics with bioinformatics and machine learning.

Tagomics has raised more than £9 million to date from investors including Calculus Capital, Illumina Ventures, IQ Capital, Agilent Ventures, Mercia Ventures, Meltwind, OMX Ventures and Start Codon.

The company has launched a new brand identity and website alongside LiquiPath, reflecting its broader focus on organ health monitoring and the development of precision medicine applications.

Tagomics is now inviting additional drug developers to participate in its LiquiPath early access programme as it works to validate applications and shape the platform's future capabilities.